Plasma NfL can be used as a non-invasive biomarker of neurodegeneration in AD patients, and the faster the NfL level rises, the faster the deterioration of overall cognitive performance (Brosseron et al., 2014). This evidence concerns the gene NEFL and Alzheimer disease.